Dimitar Efremov, MD, PhD, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy, discusses how treatment resistance in chronic lymphocytic leukemia (CLL) is mediated by interactions with the cell’s microenvironment. Interaction with B-cell receptors, toll-like receptors, T-cells and macrophages are important in activating signaling pathways for primary proteins. Using cas9, we can understand how selective genetic lesions impact leukemia development, progression and resistance. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.
